当前位置:
首页>产品中心>单抗/多抗>Obiltoxaximab ELISA Kit|奥比托沙西单抗ELISA检测试剂盒(靶标:奥比托沙西单抗酶联免疫检测试剂盒)
Obiltoxaximab ELISA Kit|奥比托沙西单抗ELISA检测试剂盒(靶标:奥比托沙西单抗酶联免疫检测试剂盒)
- 货号:RB9TDN898018
- 价格:面议
- 点击:405
产品介绍
产品参数
| 应用 | ELISA |
|---|
| 检测方法 | Colorimetric |
|---|
| 灵敏度 | 0.156 μg/ml |
|---|
| 检测范围 | 0.31-5 μg/mL |
|---|
| 回收率 | 80-120% |
|---|
| 样本类型 | Plasma, Serum |
|---|
| 检测类型 | Quantitative |
|---|
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| 运输条件 | 2-8 ℃ |
|---|
| 登录号 | P13423 |
|---|
| 背景信息 | Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax. |
|---|
| 别名 | ETI-204, 1351337-07-9 |
|---|
| 备注 | For Research Use Only. |
|---|
【仅供科学研究使用】
相关产品: